Stockscreener 앱 받기
99.73
4.09%
-4.25
전일 마감가:
$103.98
열려 있는:
$104.14
하루 거래량:
252.49K
Relative Volume:
1.05
시가총액:
$1.18B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+7.92%
1개월 성능:
+3.02%
6개월 성능:
+250.91%
1년 성능:
+654.39%
1일 변동 폭
$99.18
$104.14
1주일 범위
$90.85
$106.27
52주 변동 폭
$12.10
$114.69
Palvella Therapeutics Inc Stock (PVLA) Company Profile
명칭
Palvella Therapeutics Inc
전화
(484) 253-1461
주소
353 W. LANCASTER AVENUE, WAYNE
PVLA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
99.73 | 1.23B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 개시 | Mizuho | Outperform |
| 2025-12-05 | 개시 | BTIG Research | Buy |
| 2025-12-04 | 개시 | Craig Hallum | Buy |
| 2025-11-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2025-09-09 | 개시 | Oppenheimer | Outperform |
| 2025-08-06 | 개시 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-04-09 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-26 | 개시 | Stifel | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-20 | 개시 | Canaccord Genuity | Buy |
| 2025-02-05 | 개시 | TD Cowen | Buy |
| 2024-12-26 | 개시 | H.C. Wainwright | Buy |
| 2024-12-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-03-13 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | 개시 | Robert W. Baird | Outperform |
| 2018-03-19 | 개시 | Evercore ISI | Outperform |
| 2018-03-19 | 개시 | Jefferies | Buy |
| 2018-01-16 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-30 | 개시 | Rodman & Renshaw | Buy |
| 2016-08-05 | 재개 | ROTH Capital | Buy |
| 2015-08-12 | 개시 | JMP Securities | Mkt Outperform |
| 2015-07-27 | 개시 | Oppenheimer | Outperform |
| 2015-07-22 | 개시 | ROTH Capital | Buy |
모두보기
Palvella Therapeutics Inc 주식(PVLA)의 최신 뉴스
Analyst Calls: Is Palvella Therapeutics Inc stock forming a cup and handle2025 Technical Patterns & Weekly Top Gainers Alerts - baoquankhu1.vn
Palvella’s QTORIN pipeline targets a breakout moment in rare skin care - MSN
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Short Interest Up 60.9% in December - MarketBeat
Pharma News: Is Palvella Therapeutics Inc a turnaround storyWeekly Investment Summary & Technical Buy Zone Confirmation - baoquankhu1.vn
Moving Averages: Will Palvella Therapeutics Inc stock reach all time highs in 2025 - Bộ Nội Vụ
Aug Action: Will Palvella Therapeutics Inc stock reach all time highs in 2025 - Bộ Nội Vụ
Aspiriant LLC Acquires Shares of 5,852 Palvella Therapeutics, Inc. $PVLA - Defense World
Palvella Highlights QTORIN Pipeline and 2026 Growth Outlook - TipRanks
Palvella Therapeutics, Inc. Advances Rare Disease Therapies - TradingView — Track All Markets
Assessing Palvella Therapeutics (PVLA) Valuation After Strong One Year Returns And Conflicting Signals - Yahoo Finance
Palvella’s QTORIN Pipeline Targets a Breakout Moment in Rare Skin Care - MyChesCo
Palvella Therapeutics Joins Russell 3000 and Russell 2000 Indexes - MSN
Palvella Therapeutics provides corporate update and 2026 outlook - marketscreener.com
Palvella Therapeutics Provides Corporate Update And 2026 Outlook - TradingView — Track All Markets
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies - The Manila Times
A new gel that could become the first treatment for rare skin diseases - Stock Titan
Palvella Taps Veteran Dermatology Executive to Steer Medical Affairs Push - MyChesCo
Will Palvella Therapeutics Inc. (PI6) stock benefit from commodity supercycleForecast Cut & Proven Capital Preservation Methods - Улправда
Will Palvella Therapeutics Inc. stock maintain growth storyMarket Growth Summary & Low Drawdown Investment Ideas - Улправда
Palvella Therapeutics stock maintains Buy rating at TD Cowen ahead of key trial data - Investing.com Canada
Why analysts recommend Palvella Therapeutics Inc. (PI6) stockJuly 2025 Big Picture & Advanced Swing Trade Entry Alerts - Улправда
What is the fair value of Palvella Therapeutics Inc. stock now2025 Support & Resistance & Verified Technical Trade Signals - ulpravda.ru
Will Palvella Therapeutics Inc. stock pay special dividendsPortfolio Return Report & Low Risk High Reward Ideas - Улправда
BTIG Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA) - The Globe and Mail
Palvella Therapeutics, Inc. (PVLA) Stock Analysis: Unveiling an 82% Potential Upside in Biotech - DirectorsTalk Interviews
Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Mizuho - Defense World
Early Trial Data Puts Aclaris’ ATI-052 on Fast Track Toward Bigger Bets - MyChesCo
Aug Swings: Will Palvella Therapeutics Inc stock maintain growth storyJuly 2025 Technicals & High Accuracy Buy Signal Tips - moha.gov.vn
Mizuho Initiates Coverage of Palvella Therapeutics (PVLA) with Outperform Recommendation - Nasdaq
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Up 6.5%Here's What Happened - MarketBeat
Palvella Therapeutics Appoints Vimal Patel, PharmD, as Senior Vice President of Medical Affairs - citybiz
Palvella Therapeutics Strengthens Leadership Team with - GlobeNewswire
Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs - Sahm
Mizuho initiates coverage on Palvella Therapeutics stock with Outperform rating - Investing.com Canada
Palvella Therapeutics Secures New Patent for QTORIN™ Rapamycin - MSN
Stock Watch: Biotech Acquisitions Drive Sector Momentum Going Into 2026 - Citeline News & Insights
Earnings Recap: Will Palvella Therapeutics Inc stock pay special dividendsEarnings Recap Report & Free Real-Time Volume Trigger Notifications - Bộ Nội Vụ
Palvella Therapeutics (NASDAQ:PVLA) Trading Down 4.9% – What’s Next? - Defense World
Stifel Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - MSN
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Down 4.9%Here's What Happened - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Up 3.9% – Still a Buy? - Defense World
Palvella Therapeutics (NASDAQ:PVLA) Trading Up 3.9%Should You Buy? - MarketBeat
12 Overlooked Stocks That Delivered Massive Gains In 2025 - RTTNews
Palvella Therapeutics (NASDAQ:PVLA) Shares Up 4.1% – Should You Buy? - Defense World
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Will Palvella Therapeutics Inc. (PI6) stock enhance shareholder valueSector-Based Investing & Free Proven Portfolio Growth Strategies - Bollywood Helpline
Palvella Therapeutics (NASDAQ:PVLA) Shares Up 4.1%Time to Buy? - MarketBeat
Aclaris Joins Nasdaq Biotech Index, Marking Milestone for Clinical-Stage Firm - MyChesCo
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Down 5.9%Here's What Happened - MarketBeat
Published on: 2025-12-23 22:49:55 - bollywoodhelpline.com
Palvella Therapeutics Inc (PVLA) 재무 분석
Palvella Therapeutics Inc (PVLA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):